#United States #New York #Class Action #Gross Law Firm #Soleno Therapeutics

Soleno Therapeutics Investors Alerted

In a recent announcement, The Gross Law Firm has issued a notice concerning potential legal action for shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Those who acquired shares during a specific class period are being encouraged to reach out for possible lead plaintiff appointment in a forthcoming securities class action lawsuit. Notably, this appointment is not a prerequisite for participating in any recovery.

Investors considering to join the class action should be aware of the critical details surrounding the case. The class period is defined as running from March 26, 2025, to November 4, 2025. Allegations against Soleno include accusations of issuing materially false and misleading statements regarding the safety and effectiveness of its product, diazoxide choline extended-release tablets, also referred to as DCCR. It is claimed that the company failed to adequately disclose safety concerns related to fluid retention risks observed in clinical trial participants, which if proven true, could significantly impact the commercial viability of DCCR.

Allegations and Concerns

The complaints make several serious claims:

• - Misrepresentation of Trial Safety: It is alleged that Soleno downplayed safety concerns tied to DCCR's use for treating hyperphagia in individuals with Prader-Willi syndrome (PWS).
• - Concealment of Risks: Claims indicate that there was a lack of transparency regarding the potentially heightened safety risks associated with the drug's administration.
• - Impact on Market Performance: Following these issues, there are assertions that the viability of DCCR in the market was significantly lower than represented, leading to concerns about patient retention, prescriber confidence, and potential regulatory consequences.

Importance for Shareholders

Shareholders of Soleno Therapeutics are urged to act promptly, as the deadline for registering for the class action is set for May 5, 2026. Failure to register may result in the inability to join the proceedings. Enrolling as a shareholder not only provides updates regarding the case's progression but also ensures active participation in discussions surrounding the lawsuit.

Moreover, The Gross Law Firm has established itself as a beacon of hope for investors affected by deceitful corporate practices. Their commitment to protecting investor rights and advocating for ethical business conduct sets them apart in the legal landscape.

Next Steps for Interested Investors

After registration, affected shareholders will gain access to a portfolio monitoring software, which will keep them informed about further developments in this case. Interested parties can register through the provided link for necessary updates concerning the legal proceedings and potential recovery avenues.

Contact The Gross Law Firm

For shareholders seeking more information about the class action or the registration process, The Gross Law Firm can be reached at:

• - Website: Gross Law Firm Contact
• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Phone: (646) 453-8903
• - Email: [email protected]

The stakes are high for investors of Soleno Therapeutics as they navigate potential losses stemming from alleged corporate wrongdoing. It is crucial for affected parties to remain vigilant and proactive in protecting their investments during this challenging period.